Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

July 30, 2019

RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its second-quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019. The company will host a conference call and webcast at 4:30 PM EDT to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Thursday, August 8, 2019
   
Time: 4:30 PM EDT
   
Domestic: 800-347-6311
   
International: 720-543-0197
   
Passcode: 868 4665
   
Webcast: http://public.viavid.com/index.php?id=135544

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. For more information, please visit us https://bdsi.com or follow us on Facebook or Twitter BDSI @BioDeliverySI.

© 2019 BioDelivery Sciences International, Inc. All rights reserved.

Contact
Mary Coleman
Vice President, Investor Relations and Corporate Communications
BioDelivery Sciences International, Inc.
919-582-9050
mcoleman@bdsi.com

BioDelivery Sciences logo

Source: BioDelivery Sciences International, Inc.

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon